Triple therapy for hepatitis C in previous non-responders: a review of the clinical effectiveness and safety
CADTH
Record ID 32016000174
English
Authors' recommendations:
In general, findings from the included studies were consistent on the superiority of simeprevir once daily plus PR therapy to placebo plus PR therapy in terms of SVR in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior PR therapy. The addition of simeprevir to PR was well tolerated generally, with comparable adverse events rates compared to PR alone. The literature search did not identify evidence on sofosbuvir. There was a lack of evidence on patients with HCV genotypes 2, 3 or 4.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/sites/default/files/pdf/htis/dec-2014/RC0613%20Triple%20Therapy%20for%20Hep%20C%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Simeprevir
- Ribavirin
- Hepacivirus
- Hepatitis C
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.